



APPLICATION NOTE

Liquid Chromatography/ Mass Spectrometry

Author:

Sharanya Reddy

PerkinElmer, Inc.
Shelton, CT

Testing and Quantification of Opioids in Urine by UHPLC-TOF

Introduction

The Centers for Disease Control and Prevention report that nearly three out of four prescription drug overdoses involve prescription pain killers¹ and that death rates involving opioid analgesic abuses have more than tripled in the U.S since 1999².

We present a study for screening of opioids along with the quantitation of the drugs in urine using a time-of-flight (TOF) mass spectrometer (MS) for use in forensic laboratories.

Testing of opioids is most commonly done using the Enzyme Multiple Immunoassay Test (EMIT). Immunoassays suffer from non-specificity as they can only identify a class of drugs and cannot identify the specific compound within the class. As an example, an immunoassay for the SAMHSA panel screens for opiates such as codeine and morphine but would not detect opioids such as oxycodone, which is a semi-synthetic compound. This non-specificity can lead to false positive or false negative results, needing confirmation by techniques such as GC/MS.

GCMS assays offer their own challenges, since they require derivatization of the analytes to make them volatile for GC analysis. Derivatization chemistry is not always quantitative and can be time-consuming and limit high throughput analysis. Unlike GC/MS, LC/MS based techniques do not require time consuming derivatization of samples. Among the LC techniques, LC/MS/MS (using tandem quadrupole instrumentation) is often used to quantitate compounds in biological fluids due to its sensitivity and selectivity. However, LC/MS/MS assays are only suitable for targeted analysis, which can be an issue for forensic toxicologists who are frequently faced with the challenge of looking for unknown compounds in samples. TOF mass spectrometers, unlike tandem quadrupole instruments, collect full spectrum information without the loss of sensitivity observed with scanning instruments, which allows for simultaneous targeted and non-targeted analyses, making them ideal to use in forensic laboratories.

Experimental

A workflow for the testing and quantification of opioids is shown in Figure 1.

Calibration Curve(s)

Urine (0.5 mL) was diluted with 0.5 mL of water containing varying concentrations of a mixture of opioids. Sample (7 μ L) injected on column. Each calibration level was injected five times.

LC conditions:

Pump: PerkinElmer Flexar™ FX-15 UHPLC pump
Flow: 0.4 mL/min
Mobile phase A: Water (0.1% formic acid)

Mobile phase B: 50/50 acetonitrile/methanol (0.1% formic acid)

Gradient conditions: 5% B to 50% B in 4 min. (linear gradient), from 50% B to 90%B for next 1.0 min., maintained for an additional 1 min.

Injection volume: 7 μ L in partial loop mode

Column: PerkinElmer Brownlee™ SPP C-18, 2.1x100 mm, 2.7 μ m (part number N9308404), 25 °C

MS conditions:

Mass spectrometer: PerkinElmer AxION® 2 TOF MS

Ionization source: PerkinElmer Ultraspray™ 2 (Dual ESI source)

Ionization mode: Positive

Internal calibration was performed using m/z 195.0876 and 622.02896 as lock mass ions.

Results

Testing/Confirmation

The full spectral information provided by the TOF allows for the testing of hundreds of compounds that may be present in the sample without pre-defining them prior to analysis. Powerful software tools such as AxION Solo™ software is utilized to rapidly identify the presence or absence of compounds in large batches of samples (Figure 2). The software identifies the presence of a compound based on accurate mass and isotope profile ratio as shown in Figure 3. In addition to searching against spectral information, the software can also search for target analytes based on user defined retention time windows, which further improves the specificity of detection. Even after acquisition of data, the samples can be re-examined for presence of other







Figure 1. Workflow for testing, identification and quantification of opioids in urine.



compounds that may be in the sample by simply adding these to the target list in the software and extracting their masses from the individual chromatograms. The analysis of opioids was completed in six minutes with all the compounds eluting in less than five minutes (Figure 4).

Quantification

The overall assay sensitivity was determined to be in the 1-10 ng/mL range for all of the compounds spiked into urine, (Table 1). The limit of quantification (LOQs) measured by the TOF instrument were 200-2000 times more sensitive than what is required by the non-specific EMIT immunoassays for majority of the opioids (with the exception of 6 acetyl-morphine, which has a cut off of 10 ng/mL). When analyzing such low levels of compound, carryover must be assessed to ensure that the assay is suitable for use. In spite of the low LOQs provided by the TOF MS, 0% carryover was observed after injection of 1 µg/mL (1000 ng/mL) standard for most of the opioids.

The linearity of a representative drug, normeperidine is shown in Figure 5. The assay showed linearity over four orders with an r^2




Table 1. Shows the LOQs of the opioids in urine.

Analyte	LOQ (ng /mL)
Normeperidine	1
Tramadol	2
Norproxyphene	10
Proxyphene	1
EDDP	1
Methadone	1
Meperidine	1
Norfentanyl	2
Fentanyl	1
Naloxone	10
Oxymorphone	10
Hydromorphone	5
Hydrocodone	10
Morphine	10
Norbuprenorphine	2
Buprenorphine	2
6-acetyl morphine (6-AM)	5
Codeine	10

value of 0.997. The majority of the opioids analyzed showed linearity between 3-4 orders of dynamic range with r^2 values of 0.99 (Table 2). Multiple injections ($n=5$) of each calibration level showed excellent reproducibility ($RSDs < 15\%$) for each of the drugs. The presence of a given drug in a urine sample can be confirmed by accurate mass and the isotope profile provided by TOF MS. As shown in Table 3, the accurate masses of each of the opioids are < 5 ppm.

Conclusions

The method required little to no sample preparation or method development, saving hours of time and the use of costly reagents and consumables. The AxION 2 TOF was easily able to identify opioids spiked in urine at concentrations as low as 1-10 ng/ml. The detection limits of these drugs were 200-2000 times lower than that required by immunoassays. The AxION 2 TOF provides wide dynamic range capabilities similar to that of a triple quadrupole mass spectrometer, and also offers the screening of untargeted compounds and the ability to retrospectively look for analytes in the data set. For rapid large scale screening of batches of samples, PerkinElmer AxION Solo software provides a quick and easy platform for forensic laboratories to detect the presence or absence of opioids in urine.



















Table 2. Shows the linear dynamic range and regression for each of the opioids spiked in urine as matrix.

Analyte	Concentration range (ng/mL)	r ²
Normeperidine	1-10,000	0.997
Tramadol	2-2500	0.997
Norpropoxyphene	10-5000	0.991
Propoxyphene	1-2500	0.994
EDDP	1-5000	0.997
Methadone	1-2500	0.997
Meperidine	1-2500	0.996
Norfentanyl	2-10,000	0.996
Fentanyl	1-5000	0.996
Naloxone	10-10,000	0.997
Oxymorphone	10-20,000	0.997
Hydromorphone	5-20,000	0.997
Hydrocodone	10-10,000	0.997
Morphine	10-10,000	0.995
Norbuprenorphine	2-0,000	0.992
Buprenorphine	2-2500	0.995
6-acetyl morphine (6-AM)	5-10,000	0.995
Codeine	10-10,000	0.996

References

1. <http://www.cdc.gov/homeandrecreationalafety/rxbrief/>
2. <http://www.cdc.gov/nchs/data/databriefs/db22.pdf>

Table 3. Shows the theoretical mass, observed mass and mass error of opioids.

Analyte	Theoretical Mass of Benzodiazepines	Observed Mass of Benzodiazepines	ppm Error	Structure
Tramadol	264.1958	264.1953	1.8 ppm	
Norpropoxyphene	326.2115	326.2102	3.9 ppm	
Propoxyphene	340.2271	340.2270	0.3 ppm	
EDDP	278.1903	278.1902	0.4 ppm	
Methadone	310.2165	310.2157	2.6 ppm	
Morphine	286.1438	286.1432	2.1 ppm	
Meperidine	248.1645	248.1637	3.2 ppm	
Norfentanyl	233.1648	233.1652	1.7 ppm	
Fentanyl	337.2274	337.2266	2.3 ppm	
Naloxone	328.1543	328.1534	2.7 ppm	
Oxymorphone	302.1387	302.1378	2.9 ppm	
Normeperidine	234.1489	234.1482	2.9 ppm	
Hydromorphone	286.1438	286.1444	2.1 ppm	
Hydrocodone	300.1594	300.1586	2.6 ppm	
Norbuprenorphine	414.2639	414.2639	0.0 ppm	
Buprenorphine	468.3108	468.3098	2.1 ppm	
6-acetyl morphine	328.1543	328.1535	2.4 ppm	
Codeine	300.1594	300.1585	2.9 ppm	

For Research Use Only. Not for Use in Diagnostic Procedures.

PerkinElmer, Inc.
940 Winter Street
Waltham, MA 02451 USA
P: (800) 762-4000 or
(+1) 203-925-4602
www.perkinelmer.com



For a complete listing of our global offices, visit www.perkinelmer.com/ContactUs

Copyright © 2013-2014, PerkinElmer, Inc. All rights reserved. PerkinElmer® is a registered trademark of PerkinElmer, Inc. All other trademarks are the property of their respective owners.

011554A_01